Analysis of secreted proteins as an in vitro model for discovery of liver toxicity markers

Journal of Proteome Research

Volumn 9, Issue 11, 2010, Pages 5794-5802

  Lewis, John A ^a   Dennis, William E ^a   Hadix, Jennifer ^a,b   Jackson, David A ^a  

^a US Army Center for Environmental Health Research   (United States)

^b SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

Author keywords

ethanol exposure; HepG2 C3A; human biomarkers; liver toxicity markers; quantitative proteomics

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER;

ALCOHOLISM; ARTICLE; BLOOD SAMPLING; CELL DEATH; CELL DISRUPTION; CELL MEMBRANE; CONTROLLED STUDY; CULTURE MEDIUM; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN SECRETION; PROTEOMICS; QUANTITATIVE ANALYSIS;

BIOLOGICAL MARKERS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DRUG-INDUCED LIVER INJURY; ETHANOL; HUMANS; LIVER; PROTEINS; PROTEOMICS;

ANIMALIA;

EID: 78149403133     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr1005668     Document Type: Article

References (37)

1. Rifai, N.; Gillette, M. A.; Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat. Biotechnol. 2006, 24, 971-983
2. Liver Disease Subcommittee of the Digestive Diseases Interagency Coordinating Committee. Action Plan for Liver Disease Research; National Institutes of Health: Bethesda, MD, 2004; pp 87 - 93.
3. Hewitt, N. J.; Lechon, M. J.; Houston, J. B.; Hallifax, D.; Brown, H. S.; Maurel, P.; Kenna, J. G.; Gustavsson, L.; Lohmann, C.; Skonberg, C.; Guillouzo, A.; Tuschl, G.; Li, A. P.; LeCluyse, E.; Groothuis, G. M.; Hengstler, J. G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies Drug Metab. Rev. 2007, 39, 159-234
4. Flynn, T. J.; Ferguson, M. S. Multiendpoint mechanistic profiling of hepatotoxicants in HepG2/C3A human hepatoma cells and novel statistical approaches for development of a prediction model for acute hepatotoxicity Toxicol. in Vitro 2008, 22, 1618-1631
5. Westerink, W. M.; Schoonen, W. G. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells Toxicol. in Vitro 2007, 21, 1592-1602
6. Westerink, W. M.; Schoonen, W. G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells Toxicol. in Vitro 2007, 21, 1581-1591
7. Kelly, J. H.; Darlington, G. J. Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2 In Vitro Cell. Dev. Biol. 1989, 25, 217-222
8. Kelly, J. H. Permanent human hepatocyte cell line and its use in a liver assist device (LAD). United States Patent No. 5, 1994; pp 290 - 684.
9. Kelly, J. H.; Sussman, N. L. A fluorescent cell-based assay for cytochrome P- 450 isozyme 1A2 induction and inhibition J. Biomol. Screen 2000, 5, 249-254
10. Gislason, G. T.; Lobdell, D. D.; Kelly, J. H.; Sussman, N. L. A treatment system for implementing an extracorporeal liver assist device Artif. Organs 1994, 18, 385-389
11. De Minicis, S.; Brenner, D. A. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex J. Gastroenterol. Hepatol. 2008, 23, S98-103
12. Schaffert, C. S.; Duryee, M. J.; Hunter, C. D.; Hamilton, B. C., III; DeVeney, A. L.; Huerter, M. M.; Klassen, L. W.; Thiele, G. M. Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease World J. Gastroenterol. 2009, 15, 1209-1218
13. Albano, E. New concepts in the pathogenesis of alcoholic liver disease Expert Rev. Gastroenterol. Hepatol. 2008, 2, 749-759
14. Hammel, P.; Couvelard, A.; O'Toole, D.; Ratouis, A.; Sauvanet, A.; Flejou, J. F.; Degott, C.; Belghiti, J.; Bernades, P.; Valla, D.; Ruszniewski, P.; Levy, P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct N. Engl. J. Med. 2001, 344, 418-423
15. Vozar, I. Serum laboratory markers for noninvasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver diseases Bratisl. Lek. Listy 2005, 106, 123-126
16. Geromanos, S. J.; Vissers, J. P.; Silva, J. C.; Dorschel, C. A.; Li, G. Z.; Gorenstein, M. V.; Bateman, R. H.; Langridge, J. I. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS Proteomics 2009, 9, 1683-1695
17. Li, G. Z.; Vissers, J. P.; Silva, J. C.; Golick, D.; Gorenstein, M. V.; Geromanos, S. J. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures Proteomics 2009, 9, 1696-1719
18. Silva, J. C.; Gorenstein, M. V.; Li, G. Z.; Vissers, J. P.; Geromanos, S. J. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition Mol. Cell. Proteomics 2006, 5, 144-156
19. Dennis, G.; Sherman, B. T.; Hosack, D. A.; Yang, J.; Gao, W.; Lane, H. C.; Lempicki, R. A. DAVID: Database for Annotation, Visualization, and Integrated Discovery Genome Biol. 2003, 4, P3
20. Huang, D. W.; Sherman, B. T.; Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat. Protoc. 2009, 4, 44-57
21. Betts, G. F.; Srivastava, D. K. The rationalization of high enzyme concentration in metabolic pathways such as glycolysis J. Theor. Biol. 1991, 151, 155-167
22. Baulac, S.; Lu, H.; Strahle, J.; Yang, T.; Goldberg, M. S.; Shen, J.; Schlossmacher, M. G.; Lemere, C. A.; Lu, Q.; Xia, W. Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains Mol. Neurodegener. 2009, 4, 12
23. Reinecke, F.; Levanets, O.; Olivier, Y.; Louw, R.; Semete, B.; Grobler, A.; Hidalgo, J.; Smeitink, J.; Olckers, A.; Van der Westhuizen, F. H. Metallothionein isoform2A expression is inducible and protects against ROS-mediated cell death in rotenone-treated HeLa cells Biochem. J. 2006, 395, 405-415
24. Röjdmark, S.; Rydvald, Y.; Aquilonius, A.; Brismar, K. Insulin-like growth factor (IGF)- 1 and IGF-binding protein-1 concentrations in serum of normal subjects after alcohol ingestion: evidence for decreased IGF-1 bioavailability Clin. Endocrinol. (Oxford) 2000, 52, 313-318
25. McClain, C. J.; Song, Z.; Barve, S. S.; Hill, D. B.; Deaciuc, I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004, 287, G497-G502
26. Heinrich, P. C.; Castell, J. V.; Andus, T. Interleukin-6 and the acute phase response Biochem. J. 1990, 265, 621-636
27. Kumagi, T.; Akbar, F.; Horiike, N.; Onji, M. Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues Clin. Biochem. 2001, 34, 189-193
28. Khoruts, A.; Stahnke, L.; McClain, C. J.; Logan, G.; Allen, J. I. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients Hepatology 1991, 13, 267-276
29. Kumar, V.; Silvis, C.; Nystrom, G.; Deshpande, N.; Vary, T. C.; Frost, R. A.; Lang, C. H. Alcohol-induced increases in insulin-like growth factor binding protein-1 are partially mediated by TNF Alcohol.: Clin. Exp. Res. 2002, 26, 1574-1583
30. Lang, C. H.; Nystrom, G. J.; Frost, R. A. Regulation of IGF binding protein-1 in hep G2 cells by cytokines and reactive oxygen species Am. J. Physiol. 1999, 276, G719-G727
31. Gressner, A. M.; Bachem, M. G. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis Semin. Liver Dis. 1990, 10, 30-46
32. Friedman, S. L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies N. Engl. J. Med 1993, 328, 1828-1835
33. Rachfal, A. W.; Brigstock, D. R. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis Hepatol. Res. 2003, 26, 1-9
34. Szabó, E.; Korpos, E.; Batmunkh, E.; Lotz, G.; Holczbauer, A.; Kovalszky, I.; Deak, F.; Kiss, I.; Schaff, Z.; Kiss, A. Expression of matrilin-2 in liver cirrhosis and hepatocellular carcinoma Pathol. Oncol. Res. 2008, 14, 15-22
35. Klatt, A. R.; Nitsche, D. P.; Kobbe, B.; Morgelin, M.; Paulsson, M.; Wagener, R. Molecular structure and tissue distribution of matrilin-3a filament-forming extracellular matrix protein expressed during skeletal development J. Biol. Chem. 2000, 275, 3999-4006
36. Yamashita, R.; Fujiwara, Y.; Ikari, K.; Hamada, K.; Otomo, A.; Yasuda, K.; Noda, M.; Kaburagi, Y. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry Mol. Cell. Biochem. 2007, 298, 83-92
37. Higa, L. M.; Caruso, M. B.; Canellas, F.; Soares, M. R.; Oliveira-Carvalho, A. L.; Chapeaurouge, D. A.; Almeida, P. M.; Perales, J.; Zingali, R. B.; Da Poian, A. T. Secretome of HepG2 cells infected with dengue virus: implications for pathogenesis Biochim. Biophys. Acta 2008, 1784, 1607-1616